Czech National Bank Buys 1,923 Shares of Biogen Inc. (NASDAQ:BIIB)

Czech National Bank boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,595 shares of the biotechnology company's stock after acquiring an additional 1,923 shares during the period. Czech National Bank's holdings in Biogen were worth $4,832,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. State Street Corp grew its stake in shares of Biogen by 3.5% in the third quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company's stock worth $1,423,747,000 after acquiring an additional 248,942 shares during the last quarter. Geode Capital Management LLC grew its position in Biogen by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,613,020 shares of the biotechnology company's stock valued at $698,062,000 after purchasing an additional 47,055 shares during the last quarter. RA Capital Management L.P. increased its stake in Biogen by 20.6% during the 3rd quarter. RA Capital Management L.P. now owns 1,184,456 shares of the biotechnology company's stock valued at $229,595,000 after purchasing an additional 202,317 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Biogen by 1.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,152,691 shares of the biotechnology company's stock worth $223,438,000 after buying an additional 18,905 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Biogen by 1.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company's stock worth $176,982,000 after buying an additional 12,319 shares in the last quarter. Institutional investors own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BIIB shares. Raymond James restated a "market perform" rating on shares of Biogen in a report on Thursday, October 10th. BMO Capital Markets cut Biogen from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $230.00 to $164.00 in a research note on Friday, December 20th. JPMorgan Chase & Co. dropped their price objective on Biogen from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Monday, November 4th. StockNews.com lowered Biogen from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 28th. Finally, Truist Financial dropped their price target on shares of Biogen from $302.00 to $220.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Sixteen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $230.00.

Biogen Price Performance

NASDAQ BIIB opened at $141.00 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. Biogen Inc. has a 12 month low of $140.87 and a 12 month high of $252.17. The stock has a market cap of $20.55 billion, a price-to-earnings ratio of 12.74, a PEG ratio of 1.74 and a beta of -0.07. The company's 50 day moving average is $156.24 and its two-hundred day moving average is $186.11.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating the consensus estimate of $3.77 by $0.31. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.43 billion. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The company's revenue was down 2.5% on a year-over-year basis. During the same period last year, the firm earned $4.36 EPS. As a group, research analysts anticipate that Biogen Inc. will post 16.43 earnings per share for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.